Skip to main content
Access Resources

MJFF Publications

671 - 680 of 7407 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • RESTRICTED
    Title: Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease
    Journal Name: Journal of Medicinal Chemistry
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1021/acs.jmedchem.2c01605
    Best OA location URL:
    Citation Count: 5
  • OPEN
    Title: Movement Disorders and SARS‐CoV‐2
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mdc3.13615
    Citation Count: 2
  • OPEN
    Title: Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000201201
    Citation Count: 5
  • OPEN
    Title: A Severe Case of Lupus Cerebritis
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903100.95793.8a
    Citation Count: 0
  • OPEN
    Title: An Observational Study on the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders Treated With Anti-CD20 Therapies
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903428.98962.0a
    Citation Count: 0
  • OPEN
    Title: Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.29284
    Citation Count: 5
  • OPEN
    Title: Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy Controls
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903096.36040.1d
    Citation Count: 0
  • OPEN
    Title: Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-022-34732-5
    Citation Count: 16
  • OPEN
    Title: Protective Association of HLA-DRB1*04 Subtypes in Neurodegenerative Diseases Implicates Acetylated Tau PHF6 Sequences
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903160.72715.2d
    Citation Count: 1
  • OPEN
    Title: Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/01.wnl.0000903320.23411.f9
    Citation Count: 0
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.